Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia von Shanafelt, Tait D, Wang, Xin V, Kay, Neil E, Hanson, Curtis A, O’Brien, Susan, Barrientos, Jacqueline, Jelinek, Diane F, Braggio, Esteban, Leis, Jose F, Zhang, Cong C, Coutre, Steven E, Barr, Paul M, Cashen, Amanda F, Mato, Anthony R, Singh, Avina K, Mullane, Michael P, Little, Richard F, Erba, Harry, Stone, Richard M, Litzow, Mark, Tallman, Martin

Volltext

Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial von Shanafelt, Tait D, Wang, Xin Victoria, Hanson, Curtis A, Paietta, Elisabeth M, O'Brien, Susan, Barrientos, Jacqueline, Jelinek, Diane F, Braggio, Esteban, Leis, Jose F, Zhang, Cong Christine, Coutre, Steven E, Barr, Paul M, Cashen, Amanda F, Mato, Anthony R, Singh, Avina K, Mullane, Michael P, Little, Richard F, Erba, Harry, Stone, Richard M, Litzow, Mark, Tallman, Martin, Kay, Neil E

Volltext

Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis von Tefferi, Ayalew, Guglielmelli, Paola, Larson, Dirk R., Finke, Christy, Wassie, Emnet A., Pieri, Lisa, Gangat, Naseema, Fjerza, Rajmonda, Belachew, Alem A., Lasho, Terra L., Ketterling, Rhett P., Hanson, Curtis A., Rambaldi, Alessandro, Finazzi, Guido, Thiele, Juergen, Barbui, Tiziano, Pardanani, Animesh, Vannucchi, Alessandro M.

Volltext

GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis von Tefferi, Ayalew, Guglielmelli, Paola, Nicolosi, Maura, Mannelli, Francesco, Mudireddy, Mythri, Bartalucci, Niccolo, Finke, Christy M., Lasho, Terra L., Hanson, Curtis A., Ketterling, Rhett P., Begna, Kebede H., Naseema Gangat, Pardanani, Animesh, Vannucchi, Alessandro M.

Volltext

MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis von Guglielmelli, Paola, Lasho, Terra L, Rotunno, Giada, Mudireddy, Mythri, Mannarelli, Carmela, Nicolosi, Maura, Pacilli, Annalisa, Pardanani, Animesh, Rumi, Elisa, Rosti, Vittorio, Hanson, Curtis A, Mannelli, Francesco, Ketterling, Rhett P, Gangat, Naseema, Rambaldi, Alessandro, Passamonti, Francesco, Barosi, Giovanni, Barbui, Tiziano, Cazzola, Mario, Vannucchi, Alessandro M, Tefferi, Ayalew

Volltext

Revised cytogenetic risk stratification in primary myelofibrosis: analysis based on 1002 informative patients von Tefferi, Ayalew, Nicolosi, Maura, Mudireddy, Mythri, Lasho, Terra L., Gangat, Naseema, Begna, Kebede H., Hanson, Curtis A., Ketterling, Rhett P., Pardanani, Animesh

Volltext

A Pilot Study of the Telomerase Inhibitor Imetelstat for Myelofibrosis von Tefferi, Ayalew, Lasho, Terra L, Begna, Kebede H, Patnaik, Mrinal M, Zblewski, Darci L, Finke, Christy M, Laborde, Rebecca R, Wassie, Emnet, Schimek, Lauren, Hanson, Curtis A, Gangat, Naseema, Wang, Xiaolin, Pardanani, Animesh

Volltext

U2AF1 mutation types in primary myelofibrosis: phenotypic and prognostic distinctions von Tefferi, Ayalew, Finke, Christy M., Lasho, Terra L., Hanson, Curtis A., Ketterling, Rhett P., Gangat, Naseema, Pardanani, Animesh

Volltext

Mutation‐enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera von Tefferi, Ayalew, Guglielmelli, Paola, Lasho, Terra L., Coltro, Giacomo, Finke, Christy M., Loscocco, Giuseppe G., Sordi, Benedetta, Szuber, Natasha, Rotunno, Giada, Pacilli, Annalisa, Hanson, Curtis A., Ketterling, Rhett P., Pardanani, Animesh, Gangat, Naseema, Vannucchi, Alessandro M.

Volltext

Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts von Tefferi, Ayalew, Mudireddy, Mythri, Mannelli, Francesco, Begna, Kebede H., Patnaik, Mrinal M., Hanson, Curtis A., Ketterling, Rhett P., Gangat, Naseema, Yogarajah, Meera, De Stefano, Valerio, Passamonti, Francesco, Rosti, Vittorio, Finazzi, Maria Chiara, Rambaldi, Alessandro, Bosi, Alberto, Guglielmelli, Paola, Pardanani, Animesh, Vannucchi, Alessandro M.

Volltext

3023 Mayo Clinic Patients With Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups von Szuber, Natasha, Mudireddy, Mythri, Nicolosi, Maura, Penna, Domenico, Vallapureddy, Rangit R., Lasho, Terra L., Finke, Christy, Begna, Kebede H., Elliott, Michelle A., Hook, C. Christopher, Wolanskyj, Alexandra P., Patnaik, Mrinal M., Hanson, Curtis A., Ketterling, Rhett P., Sirhan, Shireen, Pardanani, Animesh, Gangat, Naseema, Busque, Lambert, Tefferi, Ayalew

Volltext

Driver mutations and prognosis in primary myelofibrosis: Mayo‐Careggi MPN alliance study of 1,095 patients von Tefferi, Ayalew, Nicolosi, Maura, Mudireddy, Mythri, Szuber, Natasha, Finke, Christy M., Lasho, Terra L., Hanson, Curtis A., Ketterling, Rhett P., Pardanani, Animesh, Gangat, Naseema, Mannarelli, Carmela, Fanelli, Tiziana, Guglielmelli, Paola, Vannucchi, Alessandro M.

Volltext

Survival and Disease Progression in Essential Thrombocythemia Are Significantly Influenced by Accurate Morphologic Diagnosis: An International Study von BARBUI, Tiziano, THIELE, Juergen, MARINO, Filippo, VANNUCCHI, Alessandro M, ANTONIOLI, Elisabetta, CARRAI, Valentina, GISSLINGER, Heinz, BUXHOFER-AUSCH, Veronika, MÜLLAUER, Leonhard, CAROBBIO, Alessandra, GIANATTI, Andrea, GANGAT, Naseema, PASSAMONTI, Francesco, HANSON, Curtis A, TEFFERI, Ayalew, RUMI, Elisa, BOVERI, Emanuela, RUGGERI, Marco, RODEGHIERO, Francesco, D'AMORE, Emanuele S. G, RANDI, Maria Luigia, BERTOZZI, Irene

Volltext

Sex and degree of severity influence the prognostic impact of anemia in primary myelofibrosis: analysis based on 1109 consecutive patients von Nicolosi, Maura, Mudireddy, Mythri, Lasho, Terra L., Hanson, Curtis A., Ketterling, Rhett P., Gangat, Naseema, Pardanani, Animesh, Tefferi, Ayalew

Volltext

DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfu... von GANGAT, Naseema, CARAMAZZA, Domenica, CERVANTES, Francisco, PASSAMONTI, Francesco, TEFFERI, Ayalew, VAIDYA, Rakhee, GEORGE, Geeta, BEGNA, Kebede, SCHWAGER, Susan, VAN DYKE, Daniel, HANSON, Curtis, WENTING WU, PARDANANI, Animesh

Volltext

Is unmeasurable residual disease (uMRD) the best surrogate endpoint for clinical trials, regulatory approvals and therapy decisions in chronic lymphocytic leukaemia (CLL)? von Yang, Shenmiao, Kay, Neil E., Shi, Min, Hanson, Curtis A., Gale, Robert Peter

Volltext

One Thousand Patients With Primary Myelofibrosis: The Mayo Clinic Experience von Tefferi, Ayalew, MD, Lasho, Terra L., MT, Jimma, Thitina, MD, Finke, Christy M., BS, Gangat, Naseema, MBBS, Vaidya, Rakhee, MBBS, Begna, Kebede H., MD, Al-Kali, Aref, MD, Ketterling, Rhett P., MD, Hanson, Curtis A., MD, Pardanani, Animesh, MBBS, PhD

Volltext

Chronic myelomonocytic leukaemia: a concise clinical and pathophysiological review von Patnaik, Mrinal M., Parikh, Sameer A., Hanson, Curtis A., Tefferi, Ayalew

Volltext

Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: A collaborative study of 1027 patients von Tefferi, Ayalew, Wassie, Emnet A., Guglielmelli, Paola, Gangat, Naseema, Belachew, Alem A., Lasho, Terra L., Finke, Christy, Ketterling, Rhett P., Hanson, Curtis A., Pardanani, Animesh, Wolanskyj, Alexandra P., Maffioli, Margherita, Casalone, Rosario, Pacilli, Annalisa, Vannucchi, Alessandro M., Passamonti, Francesco

Volltext

Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendatio... von Tefferi, Ayalew, Thiele, Juergen, Orazi, Attilio, Kvasnicka, Hans Michael, Barbui, Tiziano, Hanson, Curtis A., Barosi, Giovanni, Verstovsek, Srdan, Birgegard, Gunnar, Mesa, Ruben, Reilly, John T., Gisslinger, Heinz, Vannucchi, Alessandro M., Cervantes, Francisco, Finazzi, Guido, Hoffman, Ronald, Gilliland, D. Gary, Bloomfield, Clara D., Vardiman, James W.

Volltext